Clinical Quiz: Lp(a) Recommendations for Patients from 2024 NLA Update on Use of Lipoprotein(a)
The second in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on recommendations for patients.
In recent years, few topics have attracted the same level of attention in cardiovascular medicine, particularly among lipidogists, as the evolving recognition of lipoprotein(a) [Lp(a)] as a marker of elevated risk. This evolving recognition of risk is happening in tandem with a growing knowledge base and burgeoning therapeutic pipeline.
In 2019, the National Lipid Association released a scientific statement on using Lp(a) in clinical practice. Fast-forward a half-decade to April 01, 2024, and the NLA has released an update to this statement further clarifying recommendations surrounding the use of Lp(a) in clinical practice. A 12-page document citing more than 80 references, the recommendations and insights are the subject of a 3-part clinical quiz series from HCPLive Cardiology.
The second quiz of the series, this quiz focuses on the basics surrounding recommendations for patients.
Which pharmacological therapy is recommended for patients with persistently high lipoprotein(a) levels?
Reference:
Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. Published online March 29, 2024. doi:10.1016/j.jacl.2024.03.001
Editor's note: This quiz was composed with the assistance of artificial intelligence tools.
